A clear guide to GLP-1 receptor agonists, the class of medications behind Ozempic, Wegovy, and more. Learn what they are, how they work in the body, and how the different options compare for diabetes and weight loss.
GLP-1 Agonists
"Ozempic hands" has become a widely discussed side effect linked to GLP-1 medications like semaglutide and tirzepatide. This article explains the real science behind the phenomenon, who is most at risk, and practical steps you can take to protect your skin and overall appearance during weight loss.
A new announcement promises GLP-1 weight-loss medications at just $50 per month for Medicare patients. This could dramatically shift access for millions of older and lower-income Americans. Here is what the proposal means, what questions remain, and how to prepare.
New research raises concerns that stopping and restarting GLP-1 medications like semaglutide may reduce how well they work over time. If you're considering a break from Ozempic or Wegovy due to cost or side effects, here's what the science says and what to ask your doctor.
GLP-1 medications like semaglutide and tirzepatide are best known for weight loss, but emerging research suggests they may also reduce the inflammation and pain associated with endometriosis. This article breaks down what we currently know, what's still uncertain, and how to talk to your doctor about it.
Novo Nordisk is advancing an oral version of semaglutide toward the US market, raising big questions for current and prospective GLP-1 patients. This article breaks down what oral semaglutide means for access, affordability, and your treatment options going forward.
Researchers have identified a previously unknown enzyme that degrades GLP-1 hormones in the body. In lab studies, blocking this enzyme extended semaglutide's half-life by up to 40%, pointing toward future medications that could require less frequent dosing. Here's what current and prospective patients should know.
One of the biggest fears for anyone on GLP-1 therapy is what happens when you stop. New research points to a practical metabolic reset approach that may help prevent the weight rebound that affects most people after discontinuing these medications.
When you're eating smaller portions on a GLP-1 medication, every bite counts more. That's driving a surprising trend: people on semaglutide and tirzepatide are leaning hard into bold, spicy flavors. Here's what's actually going on — and why it makes a lot of sense.
